Methods: We performed a randomized, double-blind, placebo-controlled pilot trial in 34 patients aged 18-65 years
with DSM-IV primary insomnia for ≥ 6-months. Patients were randomized to 270 mg of chamomile twice daily or
placebo for 28-days. The primary outcomes were sleep diary measures. Secondary outcomes included daytime
symptoms, safety assessments, and effect size of these measures